Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Cybin ( (TSE:CYBN) ) just unveiled an update.
On August 13, 2025, Cybin Inc. released its unaudited condensed interim consolidated financial statements for the three months ending June 30, 2025. The report highlights a significant increase in total assets to $210.8 million from $179.9 million as of March 31, 2025, driven by a rise in cash and intangible assets. However, the company also reported an increase in total liabilities, primarily due to the issuance of convertible debentures amounting to $44.5 million. The financial results indicate a strategic move to bolster its financial position, potentially impacting its market strategy and stakeholder interests.
The most recent analyst rating on (TSE:CYBN) stock is a Buy with a C$114.00 price target. To see the full list of analyst forecasts on Cybin stock, see the TSE:CYBN Stock Forecast page.
Spark’s Take on TSE:CYBN Stock
According to Spark, TipRanks’ AI Analyst, TSE:CYBN is a Underperform.
Cybin’s stock score is significantly impacted by its lack of revenue and continuous financial losses, resulting in a low valuation score. While technical indicators are neutral, positive corporate events indicate potential for future growth. However, current financial challenges remain the dominant concern.
To see Spark’s full report on TSE:CYBN stock, click here.
More about Cybin
Cybin Inc. operates in the biotechnology industry, focusing on the development of psychedelic-based therapies and products. The company is headquartered in Toronto, Ontario, and is engaged in research and development to advance mental health treatment options.
Technical Sentiment Signal: Hold
Current Market Cap: C$1.97M
Find detailed analytics on CYBN stock on TipRanks’ Stock Analysis page.